平消胶囊对手术后Ⅰ～Ⅱa期非小细胞肺癌治疗分析.docVIP

平消胶囊对手术后Ⅰ～Ⅱa期非小细胞肺癌治疗分析 　 作者：张振明 朱德成 董跃华 【摘要】 目的: 观察平消胶囊对手术后Ⅰ～Ⅱa期非小细胞肺癌的１、３年生存率，免疫功能及生存质量的影响。方法: 全部患者均经病理证实的非小细胞肺癌。根据临床和术后病理确定为Ⅰ～Ⅱa期，Karnofsky评分≥70分，年龄在35～75岁。治疗组术后两周给予平消胶囊治疗，一次４～5粒，3次/d，90d为一疗程，对照组术后不给予任何治疗。治疗结束后对两组病人的１、３年生存率，免疫功能及生存质量进行评估。结果: 治疗组１、３年生存率分别为955%、665%；对照组为940%、645%。两组１、３年生存率差异无显著性（Pgt;005），治疗组外周血T细胞亚群、T淋巴细胞的比值明显高于对照组（Plt;005）。生存质量（生活质量调查、体重、卡氏评分）明显高于对照组（Plt;005）。结论: 平消胶囊具有增加患者免疫力及提高生存质量的作用，但对术后Ⅰ～Ⅱa期非小细胞肺癌的生存率（１、３年生存率）无明显影响。 【关键词】 平消胶囊; Ⅰ～Ⅱa期非小细胞肺癌 【ABSTRACT】 Objective: To investigate the survival rate in one and three years,the immunity and living quality while the Ⅰ～Ⅱa NSCLC patients were treated with Pingxiao Capsule after operation.Methods:The patients confirmed suffering from non small cell lung cancer（NSCLC） were diagnosed being in the Ⅰ～Ⅱa period,Karnofsky≥70,35~70 years old (including 35 and 75).The group was treated with Pingxiao Capsule,4~5 capsules pertime,three times a day,taking 90 days as treating course,but the control group didnt receive any treatment.After the treatment ended,the survival rate, immunity and living quality were evaluated.Results:For the treated group,the survival rates for one and three years were 955% and 665% separately.For the control group,the rates of that were 940% and 645%.There is no significant differece between the two groups（Pgt;005）.The specific data of outside Tcell submass and limphcell in the treated group was higher than that of the control group（Plt;005）.The treated groups living quality(living quality form of questionnaire,weight,calculative mark) was higher than that of the control group（Plt;005）.Conclusion:Pingxiao Capsule has the function to improve patients immunity and living quality.But there is no remarkable affect on survival rate of the patients suffering from nonsmall cell lung cancer after operation. 【KEY WORDS】 Pingxiao Capsule;Ⅰ～Ⅱa NSCLC 手术治疗是Ⅰ～Ⅱa期非小细胞肺癌的主要治疗手段，对Ⅰ～Ⅱa期非小细胞肺癌是否常规进行化学治疗存在争议，中西医结合是我国肿瘤治疗的特色和优势。鉴于人们普遍存在的对化疗的恐惧感和对中药的易顺从性，我们于2000～2003年对30例经手术证实的Ⅰ～Ⅱa期非小细胞肺癌应用平消胶囊治疗，并进行对照，发现其